320 Index Name Paper ref. Name Paper ref. Born, W Thu 197 Borobia, AM Tue 348, Mon 451 Borrelli, E FC17.4.6 Borrelli, F Wed 307 Börresen-Dale, A-L Wed 151 Borsodi, A Wed 050 Borsotto, M Thu 237 Bosch, M FC10.4.6 Bosco, P Wed 400 Boskovic, A Wed 135 Boskovic, J Mon 127 Bosmans, G Wed 002 Bosnjak, Z Mon 373 Bossert, J FC14.3.2 Bost, JGPJ Wed 287 Bõsze, Z Mon 401 Botros, S Mon 372 Böttiger, Y Mon 371, Wed 008 Botto, H Tue 204 Botz, B Mon 110, Mon 106 Botzenhart, E W03.7 Boukraâ, L Wed 313 Boulieu, R Mon 193, Mon 263 Bounoure, F Thu 242 Bouraoui, A Wed 316 Bourinet, E FC03.2.3 Bourrel, R Tue 104 Boussaïd, M Mon 004 Boutaud, O FC05.3.6 Boutin, JA Wed 072 Bouvier, M FC11.3.1 Bouzinova, EV Wed 397, Wed 433 Boxwalla, M Wed 184 Boyd, B Thu 280 Boyden, PA FC06.1.2 Boyer, M FC04.2.5 Boyle, EM Wed 006 Bozec, E Mon 191 Bozina, N Tue 304, Wed 398, Wed 112, Mon 048, Tue 121 Božina, T Mon 048 Bozkurt, A Wed 249, Bozkurt, TE Mon 366 Bozo, T FC16.2.6 Braber, S FC09.5.2 Brabet, I FC11.3.6, Thu 083 Bradamante, V Mon 347 Bradley, SJ Wed 030 Bradnock, D Thu 214 Brain, S Thu 197 Brain, SD Mon 287 Brajovic, M FC10.1.6 Bramanti, P FC18.1.5, Mon 277, FC18.3.6, Thu 364 Brancaleone, V Thu 081, FC09.4.6 Branco, T Wed 130 Brand, L Wed 399 Brandes, RP FC15.1.1 Brasch-Andersen, C Mon 090, Tue 395, Wed 151 Brauch, H Wed 133 Bräuner-Osborne, H FC11.5.1, FC11.5.6, Wed 084, Thu 027 Breckenridge, A FC13.1.3 Bregnedal, P Mon 046 Breitkreutz, J FC10.3.2 Bremner, JD FC17.5.3 Brenneman, D Tue 389 Brennum, LT FC17.4.2 Breschi, MC Wed 442, Mon 382 Breum-Leer, C Tue 358 Briedis, V Tue 329 Briggs, JP FC16.5.4 Brink, CB W20.2, W15.3, Mon 412 Brito, GAC Mon 298, Tue 255, Wed 318, Wed 319 Brive, L Wed 092 Briyal, S FC05.2.5 Broadstock, M Wed 044 Broccardo, M Tue 249, Brochard, K FC10.5.5 Brock, B Tue 356, Tue 357, Tue 358, FC05.4.6, Thu 413 Brock, C W12.6 Brødbæk, K FC13.3.6, Mon 119, Mon 118, Mon 406 Bröer, S FC02.3.4 Brøgger, T Wed 433 Broquères-You, D Mon 232 Brørs, O Wed 139 Broselid, S Thu 047 Brøsen, K FC13.5.5, Mon 050, Mon 090, Wed 151 Brouillette, D Wed 123 Broux, F FC10.5.5 Brown, DA Wed 047 Brown, MJ PL17 Brown, VJ FC17.3.4 Brum, P Wed 042 Brune, K Tue 310 Brunet, A Mon 203, Mon 201, Mon 205, Mon 204, Mon 202 Brunetti, L Mon 105, Wed 434, Wed 329 Bruno, V Wed 400 Brusco, A Thu 176 Brussee, J FC11.2.5 Brusselle, GG FC09.5.1 Brusturean, E Mon 417, Mon 438 Bruttmann, G Tue 268 Bruun, J FC05.1.1 Bryan, K Mon 443 Bryson, P Tue 012 Brzozowska, I Tue 463 Brzozowski, T Tue 463 Buadze, M YI.02 Bubik, MF FC16.1.5 Buble, T Tue 095 Bucci, M Thu 081, Thu 202 Bucolo, C Mon 152 Bucsics, A Mon 153 Buda, S Mon 120 Budimir, A Mon 373 Bühler, FR W10.3 Bünemann, M Wed 026 Buhl, CS Mon 154 Buhl, ES Mon 154 Bui, V Mon 285 Bukarica, LG Thu 324 Bukumiric, Z Wed 436
Name Paper ref. Name Paper ref. Bult, H Wed 246, Wed 245 Bulut, G Tue 411 Bungay, P Mon 236 Buniatian, GH YI.02 Bunton, D Wed 132, Tue 160 Burande, DM FC01.1.6 Burcher, E Mon 235, FC08.1.6 Buresova, E Tue 222, Tue 421 Burgess, C Tue 136 Burggraaf, J Tue 148, Thu 214, Thu 215, Mon 316 Burggraaf, JK FC10.4.6 Burhenne, J Mon 018 Buriani, A Wed 320 Burk, O FC02.1.5 Burkhardt, T Mon 153 Burkin, DJ FC12.4.5 Burnet, M FC18.2.6 Burstein, S Mon 264 Burul-Bozkurt, N Wed 438, Mon 155 Busenlehner, LS FC11.3.2 Busija, D FC05.1.6 Busillo, V Mon 448 Busker, M Wed 210, Wed 280, Thu 252 Busserolles, J Thu 083 Bustamante, S Mon 411 Butler, A Tue 233 Butler, N Tue 110 Butterweck, V Wed 417 Buus, NH Mon 200 Buyukdeligoz, M Tue 366, Tue 449, Tue 450 Buyukuysal, RL Wed 179 Buzoianu, AD Mon 417, Mon 438, Tue 481 Bylund, DB W15.1 Byun, B-Y Wed 383 Cabal, J Tue 343, Tue 448 Cabral, A Mon 376 Cabriol, N Tue 170 Cabrita, A Tue 407, Cachimaille, Y Thu 394 Cadete, V FC06.3.6 Caduff, P W32.1 Cahalan, MD FC12.5.1 Cai, G Tue 384 Cai, Y Mon 266, Thu 277 Cailliez, M FC10.5.5 Cairns, BE W12.3 Cairrão, E Wed 211 Caisey, A Mon 232 Caixas, U Wed 130 Cakir, B Wed 249 Cakmak, A Mon 348 Cakmakci, Y Wed 308 Calapai, G Wed 317, Thu 316, Thu 364 Calignano, A FC18.1.6 Caliskan, F Mon 348 Callado, LF Wed 031, Thu 399 Callahan, M Tue 372 Callegari, E Mon 236 Calloe, K FC06.1.4 Callreus, T Mon 345 Calmettes, Y Tue 170 Calou, I Mon 299, Mon 298, Wed 318, Wed 319 Calvet, D Mon 191 Calvo Duo, R Tue 197 Calvo, A Mon 007, Tue 261 Calvo, R Wed 111 Camacho, E Wed 212 Camarasa, J Wed 174, Wed 177, Wed 181, Thu 179 Camargo, LL Wed 237 Camici, PG FC05.2.2 Camins, A Mon 443 Camm, AJ FC06.2.1 Camparo, P Tue 204 Campbell, A Wed 032 Campbell, AP Wed 048 Campbell, WB FC15.3.4 Campos, A Mon 451 Campos, M Wed 337 Campos-Toimil, M Wed 359, Wed 227 Can, C Thu 233 Canals, M Thu 060 Candeletti, S FC14.1.5 Canet, E PL04 Cantilena, L Tue 107 Cao, D Thu 020 Cao, G Mon 349 Cao, L Wed 034 Cao, Lei Wed 213, Wed 033 Cao, N Thu 280 Cao, Y Tue 418, Tue 173, Tue 325, Wed 327, Tue 035 Cao, Y-B Mon 265 Cao, Y-X Mon 266, Wed 034 Cao, Y Mon 008 Cao, Y-X Tue 298, Wed 213, Wed 033 Cap, R Tue 421 Capasso, A Tue 406, Tue 487, Mon 448, Tue 488, Mon 449 Capasso, F Wed 307 Capasso, R Wed 307 Capdeville-Atkinson, C Wed 244 Capellà, D FC14.4.5 Caputi, A FC04.4.5, FC04.3.6 Caputi, F FC14.1.5 Cara, D Tue 229 Caraci, F Wed 400 Carageorgiou, H Tue 457 Caramona, MM Mon 350, Mon 376, Thu 119, Wed 214 Carbonell, N W02.2.6 Carbonneau, C Tue 396 Carcak, N Mon 418 Carcas, AJ Mon 451 Carcas-Sansuán, AJ Tue 348 Cardell, LO Mon 266 Cardell, L-O Tue 292 Cardeso, ALC Mon 125 Cardoso, J Tue 420 Carle, F FC04.3.6 Carleton, B FC10.5.2, Thu 019, Thu 020 Carlier, P FC04.2.5 Carling, R Thu 088 Carlsson, L FC06.2.2 Carmo, A Tue 397 Carnero, M Thu 240, Wed 215, Mon 206 Index 321
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273: FC16 Natural products: Past and fut
- Page 274 and 275: FC16 Natural products: Past and fut
- Page 276 and 277: FC17 New approaches and targets in
- Page 278 and 279: FC17 New approaches and targets in
- Page 280 and 281: W34 State-of-the-art of basic and c
- Page 282 and 283: FC10 Drugs for half the world: Paed
- Page 284 and 285: FC11 G protein-coupled 7TM receptor
- Page 286 and 287: FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373:
370 Index Name Paper ref. Name Pape
- Page 374 and 375:
372 Index Name Paper ref. Name Pape
- Page 376 and 377:
374 Index Name Paper ref. Name Pape
- Page 378 and 379:
376 Index Name Paper ref. Name Pape
- Page 380 and 381:
378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor